NexImmune (NASDAQ:NEXI) PT Raised to $7.00 at Barclays

NexImmune (NASDAQ:NEXI – Get Rating) had its target price boosted by Barclays from $4.00 to $7.00 in a report issued on Friday, The Fly reports. They currently have an overweight rating on the stock. Several other equities analysts have also recently weighed in on the stock. Cantor Fitzgerald reiterated an overweight rating on shares of […]

Related Keywords

Manhattan ,New York ,United States ,Blackrock ,Raymond James ,Solj Barer ,Kristi Jones ,Geode Capital Management ,Zacks Investment Research ,Blackrock Inc ,First Manhattan Co ,Neximmune Company Profile Get Rating ,Cantor Fitzgerald ,Neximmune Inc ,Barclays ,Get Rating ,Director Sol ,Capital Management ,Street Corp ,Immune Company Profile ,Artificial Immune Modulation ,Neximmune ,Nasdaq Nexi ,Nexi ,Medical ,Boost Price Target ,Barclays Plc ,